Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
13.17
+0.20 (1.54%)
Jul 30, 2026, 1:24 PM EDT - Market open
Lyell Immunopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.03 | 0.04 | 0.06 | 0.13 | 84.68 | 10.65 | |
Revenue Growth | -52.31% | -40.98% | -53.08% | -99.85% | 695.15% | 37.31% |
Gross Profit | 0.03 | 0.04 | 0.06 | 0.13 | 84.68 | 10.65 |
Selling, General & Admin | 40.64 | 45.14 | 52.04 | 66.98 | 117.31 | 89.06 |
Research & Development | 151.83 | 225.01 | 258.79 | 182.95 | 159.19 | 138.69 |
Other Operating Expenses | -3.92 | -0.7 | 47.99 | -2.79 | -4.75 | -2.32 |
Total Operating Expenses | 188.55 | 269.44 | 358.82 | 247.14 | 271.74 | 225.43 |
Operating Income | -256.3 | -269.4 | -358.76 | -247.01 | -187.06 | -214.78 |
Interest Income | 11.41 | 13.08 | 24.07 | 23.45 | 7.05 | 1.17 |
Other Non-Operating Income (Expense) | 4.86 | -18.12 | -8.31 | -11.08 | -3.11 | -36.61 |
Total Non-Operating Income (Expense) | 9.89 | -5.04 | 15.76 | 12.38 | 3.94 | -35.44 |
Pretax Income | -246.41 | -274.45 | -342.99 | -234.63 | -183.12 | -250.22 |
Net Income | -246.41 | -274.45 | -342.99 | -234.63 | -183.12 | -250.22 |
Net Income to Common | -246.41 | -274.45 | -342.99 | -234.63 | -183.12 | -250.22 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 19 | 17 | 13 | 13 | 12 | 7 |
Shares Outstanding (Diluted) | 19 | 17 | 13 | 13 | 12 | 7 |
Shares Change | 38.86% | 30.74% | 4.18% | 1.58% | 81.79% | 925.18% |
EPS (Basic) | -13.80 | -16.06 | -26.23 | -18.70 | -14.80 | -36.80 |
EPS (Diluted) | -13.80 | -16.06 | -26.23 | -18.70 | -14.80 | -36.80 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -134.42 | -150.8 | -162.86 | -166.38 | -193.83 | -191.75 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -7.13 | -8.82 | -12.46 | -13.26 | -15.69 | -28.22 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -826768.00% | -748344.00% | -588123.00% | -190006.00% | -220.89% | -2016.68% |
Profit Margin | -794858.00% | -762356.00% | -562285.00% | -180486.00% | -216.24% | -2349.47% |
FCF Margin | -433610.00% | -418900.00% | -266980.00% | -127985.00% | -228.89% | -1800.50% |
EBITDA | -245.87 | -257.87 | -339.12 | -226.76 | -169.04 | -201.15 |
EBITDA Margin | -793123.00% | -716292.00% | -555941.00% | -174429.00% | -199.61% | -1888.75% |
EBIT | -256.3 | -269.4 | -358.76 | -247.01 | -187.06 | -214.78 |
EBIT Margin | -826768.00% | -748344.00% | -588123.00% | -190006.00% | -220.89% | -2016.68% |